Eyexora has announced its launch as the first company to accelerate ophthalmology innovation using a hub-and-spoke model. The company, which is building a global portfolio, has initiated collaborations in Singapore and Europe, with its initial assets in-licensed from the Singapore Eye Research Institute (SERI).
The seed financing for Eyexora was led by life sciences investor ClavystBio, with contributions from leading ophthalmology experts. The company aims to advance a diversified portfolio of anterior and posterior segment therapeutics and ophthalmic devices within a $50 billion global market that serves over two billion patients.
Eyexora’s innovative approach addresses the inefficiencies of traditional drug development by centralising scientific, clinical, regulatory, and commercial expertise in a shared operational hub. This hub supports its subsidiaries, each dedicated to a distinct therapeutic or technology programme, enabling scalable growth whilst mitigating risk.
Headquartered in the US, Eyexora plans to establish global subsidiaries to support its business model. The company was co-founded by leaders in ophthalmology with decades of industry experience.
Eyexora’s launch marks a significant step in the evolution of ophthalmology, promising faster and more efficient delivery of eye care solutions worldwide.
